Resource Library
Filter Resources
Area of Interest
- Select All
- Immunoscore® Colon
- Biopharma Services
- IVD Services
- Immunoscore® Rectum
- Corporate
- Immunoscore®
Resource Type
- Select All
- Brochure
- Poster
- Webinar
- Video
- Publication
Poster
Immunoscore® analytical performance
Poster
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study
Poster
Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial
Poster
A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections
Poster
Immunoscore IC (previously Halioseek® PD‐L1/CD8), a dual CD8 and PD‐L1 IVD assay to improve NSCLC patients stratification
Poster
LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study
Poster
Immunoscore provides prognostic information in low (T3N1) and high (T4 or N2) risk subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)
Poster
Multi-centric PD-L1 and CD8 IHC assessment in NSCLC using IMMUNOSCORE® IC previously Halioseek®) CE-IVD assay
Poster
A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors
Poster